HCM News and Press, HUTCHMED (China) Limited From 01/10/24

— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 — — NDA is supported by data from successful Phase III ESLIM-01 trial in patients with adult primary immune thrombocytopenia who have received at least ...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that under the 2023 simple renewal mechanism of the China National Healthcare Security Admini...

HONG KONG, Shanghai and FLORHAM Park, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:​HCM, HKEX:​13) (“ HUTCHMED ”) today announces that it has completed enrollment of its Phase II/III trial of fruquintinib in combination with sintilim...

2023-12-12 12:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-01 10:35:40 ET Summary HUTCHMED (China)'s partner, Takeda, received FDA approval for the sale of FRUZAQLA in the US, leading to a milestone payment of $35 million for HUTCHMED (China). The approval opens up the US market for HUTCHMED (China), which was previously focused o...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Nov. 30, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today highlights that new clinical data from several ongoing studies with HUTCHMED investigational drug candi...

2023-11-24 08:54:00 ET More on Hutchison China MediTech Hutchmed: Progressing, But We Would Like More Clarity On Profit Margins Takeda wins FDA nod for colorectal cancer therapy Seeking Alpha’s Quant Rating on Hutchison China MediTech Historical earnin...

2023-11-09 07:21:50 ET More on HUTCHMED, Takeda, etc. Takeda Pharmaceutical Company Limited (TAK) Q2 2023 Earnings Call Transcript Takeda: Why I'm Staying Bearish On This Generic Drug Dividend Play Hutchmed: Progressing, But We Would Like More Clarity On Profit Margi...

— FRUZAQLA is the first targeted therapy approved in the U.S. for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in more than a decade — — U.S. approval of FRUZAQLA triggers first milestone payment from Takeda ...

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Wednesday, November 8 and Thursday, November 9, featuring live webcast presentations from international companies with American D...